Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2968661 | 0.88 | ELANE (0.33) | SMN1; SMN2ELANE | |
| SCHEMBL725985 | 0.86 | ALDH1A1 (0.44) | SMN1; SMN2 | |
| SCHEMBL728561 | 0.76 | ALDH1A1 (0.34) | ELANE | |
| SCHEMBL9861942 | 0.75 | KCNH2 (0.33) | LMNAHPGDSMN1; SMN2 | |
| SCHEMBL2965438 | 0.73 | ALDH1A1 (0.45) | SMN1; SMN2ELANE | |
| SCHEMBL2971453 | 0.71 | EED (0.33) | — | |
| SCHEMBL727390 | 0.71 | ELANE (0.35) | ELANE | |
| SCHEMBL2972448 | 0.70 | HCAR3 (0.39) | LMNAHPGDSMN1; SMN2ELANE | |
| SCHEMBL15170060 | 0.69 | HPGD (0.45) | LMNAHPGDSMN1; SMN2 | |
| SCHEMBL11409853 | 0.68 | TDP1 (0.38) | LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4797063-B2 | — | — | 2011-10-19 | — | — | JP | claimed |
| US-20080315155-A1 | Diamines Having Reduced Color | ALBEMARLE CORPORATION (US) | 2008-12-25 | — | — | US | claimed |
| EP-1966122-A1 | DIAMINES HAVING REDUCED COLOR | Albermarle Corporation (US) | 2008-09-10 | — | — | EP | claimed |
| JP-2008534585-A | — | — | 2008-08-28 | — | — | JP | claimed |
| US-20080004406-A1 | DIIMINES AND SECONDARY DIAMINES | ALBEMARLE CORPORATION (US) | 2008-01-03 | — | — | US | claimed |
| EP-1868987-A1 | DIIMINES AND SECONDARY DIAMINES | ALBEMARLE CORPORATION (US) | 2007-12-26 | — | — | EP | claimed |
| WO-2007079367-A1 | DIAMINES HAVING REDUCED COLOR | ALBEMARLE CORPORATION (US) | 2007-07-12 | — | — | WO | claimed |
| WO-2006104528-A1 | DIIMINES AND SECONDARY DIAMINES | ALBEMARLE CORPORATION (US) | 2006-10-05 | — | — | WO | claimed |
| US-20060217567-A1 | Diimines and secondary diamines | ALBEMARLE CORPORATION | 2006-09-28 | — | — | US | claimed |
| US-8212078-B2 | Making chain extenders with slower cure rates; reacting a ketone and/or aldehyde with a primary amine in the presence of an acidic ion exchange resin and hydrogenation agent; making diimine same way but excluding hydrogenation agent; e.g. N,N'-di-5-nonyl-isophoronediamine | ALBEMARLE CORPORATION (US) | 2012-07-03 | — | — | US | disclosed |
| US-7767858-B2 | Diimines and secondary diamines | ALBEMARLE CORPORATION (US) | 2010-08-03 | — | — | US | disclosed |
| EP-2143707-A2 | Secondary diamine | Albermarle Corporation (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20080315155-A1 | Diamines Having Reduced Color | ALBEMARLE CORPORATION (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080315155-A1 | Diamines Having Reduced Color | ALBEMARLE CORPORATION (US) | 2008-12-25 | — | — | US | disclosed |
| US-7288677-B2 | Diimines and secondary diamines | ALBEMARLE CORPORATION (US) | 2007-10-30 | — | — | US | disclosed |
| WO-2007079365-A2 | BLENDS OF DIAMINES HAVING REDUCED COLOR | ALBEMARLE CORPORATION (US) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007079367-A1 | DIAMINES HAVING REDUCED COLOR | ALBEMARLE CORPORATION (US) | 2007-07-12 | — | — | WO | disclosed |
| WO-2006104528-A1 | DIIMINES AND SECONDARY DIAMINES | ALBEMARLE CORPORATION (US) | 2006-10-05 | — | — | WO | disclosed |
| US-20060217567-A1 | Diimines and secondary diamines | ALBEMARLE CORPORATION | 2006-09-28 | — | — | US | disclosed |
| US-3943158-A | POLYURETHANE MONOMERS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004406-A1 | DIIMINES AND SECONDARY DIAMINES | DDT, DDC, AOC1 | LMNA 3166/4885HPGD 955/4885SMN1; SMN2 3151/4885 |
| US-20080315155-A1 | Diamines Having Reduced Color | DDT, DPYD, DDC | LMNA 635/4885HPGD 427/4885SMN1; SMN2 1733/4885 |
| US-20060217567-A1 | Diimines and secondary diamines | DDT, DDC, AOC1 | LMNA 3166/4885HPGD 955/4885SMN1; SMN2 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.